Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Orziloben (NST-6179) in Subjects With Intestinal Failure-Associated Liver Disease (IFALD)

Next Previous
Trial Profile

A Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Orziloben (NST-6179) in Subjects With Intestinal Failure-Associated Liver Disease (IFALD)

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 26 Feb 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Orziloben (Primary)
  • Indications Intestinal failure; Liver disorders
  • Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
  • Sponsors NorthSea Therapeutics

Most Recent Events

  • 20 Feb 2025 According to a NorthSea Therapeutics media release, the company expects interim data from this trial in the first half of 2026.
  • 21 Feb 2024 According to a NorthSea Therapeutics media release, the readout of the trial is anticipated in H2 2025. This trial has been initiated a Phase 2a study in Q1-2024.
  • 21 Feb 2024 According to a NorthSea Therapeutics media release, company announced the dosing of the first patient in this Phase 2a clinical trial of Orziloben (NST-6179) in intestinal failure-associated liver disease (IFALD), an orphan liver disease affecting individuals on prolonged intravenous (parenteral) nutrition (PN).

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top